Inhibition of HIV-1 entry by antibodies: Potential viral and cellular targets

Journal of Internal Medicine

Volumn 262, Issue 1, 2007, Pages 26-43

  Phogat, S ^a   Wyatt, R T ^a   Karlsson Hedestam, G B ^b,c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

Envelope glycoprotein; HIV 1; Incorporated proteins; Neutralizing antibodies; Receptors; Vaccine

Indexed keywords

12G5; 5A8; ANTIBODY; CD4 ANTIGEN; CD4 IMMUNOGLOBULIN G2; CELL PROTEIN; CELL RECEPTOR; CHEMOKINE RECEPTOR CCR5; CYANOVIRIN N; GLYCOPROTEIN GP 120; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HUMAN IMMUNODEFICIENCY VIRUS 1 VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAB 004; NEUTRALIZING ANTIBODY; PHOSPHORYL LIPID A; PRO 140; Q 425; TNX 355; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS RECEPTOR;

ALLOIMMUNIZATION; ANTIBODY ISOLATION; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; SINGLE DRUG DOSE; TARGET CELL; TREATMENT DURATION; VIRUS LOAD; VIRUS TRANSMISSION;

AIDS VACCINES; EPITOPES; GENE PRODUCTS, ENV; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, HIV; VIRAL PROTEINS; VIRUS INTERNALIZATION;

EID: 34347256384     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2007.01820.x     Document Type: Conference Paper

References (154)

1. Berman PW, Gregory TJ, Riddle L et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 1990 345 : 622 5.
2. Ferrantelli F, Rasmussen RA, Hofmann-Lehmann R, Xu W, McClure HM, Ruprecht RM. Do not underestimate the power of antibodies - lessons from adoptive transfer of antibodies against HIV. Vaccine 2002 20 (Suppl. 4) : A61 5.
3. Hofmann-Lehmann R, Vlasak J, Rasmussen RA et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol 2001 75 : 7470 80.
4. Mascola JR, Lewis MG, Stiegler G et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999 73 : 4009 18.
5. Mascola JR, Stiegler G, VanCott TC et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000 6 : 207 10.
6. Veazey RS, Shattock RJ, Pope M et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003 9 : 343 6.
7. Lazzarin A, Clotet B, Cooper D et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003 348 : 2186 95.
8. Hazuda DJ, Young SD, Guare JP et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004 305 : 528 32.
9. Westby M, van der Ryst E. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother 2005 16 : 339 54.
10. Kuritzkes DR, Jacobson J, Powderly WG et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004 189 : 286 91.
11. Olson WC, Rabut GE, Nagashima KA et al. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol 1999 73 : 4145 55.
12. Lee BM, Sharron C, Blanpain BJ et al. Epitope mapping of CCRS reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem 1999 274 : 9617 26.
13. Roschke V, Moore PA. Characterization of a Panel of Novel Human Monoclonal Antibodies that Specifically Antagonize CCR5 and Block HIV-1 Entry. 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2004, #2871.
14. Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998 93 : 681 4.
15. Center RJ, Lebowitz J, Leapman RD, Moss B. Promoting trimerization of soluble human immunodeficiency virus type 1 (HIV-1) Env through the use of HIV-1/simian immunodeficiency virus chimeras. J Virol 2004 78 : 2265 76.
16. Center RJ, Schuck P, Leapman RD et al. Oligomeric structure of virion-associated and soluble forms of the simian immunodeficiency virus envelope protein in the prefusion activated conformation. Proc Natl Acad Sci U S A 2001 98 : 14877 82.
17. Chertova E, Bess JW Jr., Crise BJ et al. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU). Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 2002 76 : 5315 25.
18. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998 280 : 1884 8.
19. Zanetti G, Briggs JA, Grunewald K, Sattentau QJ, Fuller SD. Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog 2006 2 : e83.
20. Zhu P, Liu J, Bess J Jr. et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006 441 : 847 52.
21. Trkola A, Purtscher M, Muster T et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996 70 : 1100 8.
22. Wei X, Decker JM, Wang S et al. Antibody neutralization and escape by HIV-1. Nature 2003 422 : 307 12.
23. Goudsmit J, Debouck C, Meloen RH et al. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci U S A 1988 85 : 4478 82.
24. Kwong PD, Doyle ML, Casper DJ et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002 420 : 678 82.
25. Moore JP, Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 1996 70 : 1863 72.
26. Wyatt R, Desjardin E, Olshevsky U et al. Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein. J Virol 1997 71 : 9722 31.
27. Burton DR, Desrosiers RC, Doms RW et al. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science 2004 303 : 316.
28. Graham BS, Mascola JR. Lessons from failure - preparing for future HIV-1 vaccine efficacy trials. J Infect Dis 2005 191 : 647 9.
29. Ltd, A. I. HIV gp120 vaccine - VaxGen; AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech; HIV gp120 vaccine AIDSVAX - VaxGen; HIV vaccine AIDSVAX - VaxGen. Drugs R D 2003 4 : 249 53.
30. Phogat S, Wyatt R. Rational modification of HIV-1 envelope glycoproteins for immunogen design. Curr Pharm Des 2007 13 : 213 27.
31. Wyatt R, Kwong PD, Desjardins E et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998 393 : 705 11.
32. Burton DR, Desrosiers RC, Doms RW et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004 5 : 233 6.
33. Burton DR, Pyati J, Koduri R et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994 266 : 1024 7.
34. Posner MR, Cavacini LA, Emes CL, Power J, Byrn R. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J Acquir Immune Defic Syndr 1993 6 : 7 14.
35. Kwong PD, Zhou T, Xu L et al. Functional constraints and antibody recognition of the CD4-binding site on HIV-1 gp120. Antiviral Ther 2006 11 : 159.
36. Calarese DA, Scanlan CN, Zwick MB et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003 300 : 2065 71.
37. Muster T, Steindl F, Purtscher M et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993 67 : 6642 7.
38. Zwick MB, Labrijn AF, Wang M et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001 75 : 10892 905.
39. Ofek G, Tang M, Sambor A et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004 78 : 10724 37.
40. Cardoso RM, Zwick MB, Stanfield RL et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005 22 : 163 73.
41. Miller MD, Geleziunas R, Bianchi E et al. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A 2005 102 : 14759 64.
42. Nabel GJ. Immunology. Close to the edge: neutralizing the HIV-1 envelope. Science 2005 308 : 1878 9.
43. Baba TW, Liska V, Hofmann-Lehmann R et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000 6 : 200 6.
44. Oleske JM. This is no time to stop use of nevarapine to prevent mother-to-child transmission of HIV. AIDS 2006 20 : 1059 60.
45. Trkola A, Kuster H, Rusert P et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005 11 : 615 22.
46. Nishimura Y, Igarashi T, Haigwood NL et al. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc Natl Acad Sci U S A 2003 100 : 15131 6.
47. Gorny MK, Williams C, Volsky B et al. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J Virol 2002 76 : 9035 45.
48. Hartley O, Klasse PJ, Sattentau QJ, Moore JP. V3: HIV's switch-hitter. AIDS Res Hum Retroviruses 2005 21 : 171 89.
49. Huang CC, Tang M, Zhang MY et al. Structure of a V3-containing HIV-1 gp120 core. Science 2005 310 : 1025 8.
50. Thali M, Moore JP, Furman C et al. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 1993 67 : 3978 88.
51. Raja A, Venturi M, Kwong P, Sodroski J. CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5. J Virol 2003 77 : 713 8.
52. Moulard M, Phogat SK, Shu Y et al. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A 2002 99 : 6913 8.
53. Labrijn AF, Poignard P, Raja A et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003 77 : 10557 65.
54. Decker JM, Bibollet-Ruche F, Wei X et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 2005 201 : 1407 19.
55. Koff WC, Johnson PR, Watkins DI et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 2006 7 : 19 23.
56. Burton DR, Stanfield RL, Wilson IA. Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A 2005 102 : 14943 8.
57. Yang X, Farzan M, Wyatt R, Sodroski J. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 2000 74 : 5716 25.
58. Yang X, Lee J, Mahony EM, Kwong PD, Wyatt R, Sodroski J. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 2002 76 : 4634 42.
59. Binley JM, Sanders RW, Clas B et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 2000 74 : 627 43.
60. Chow YH, Wei OL, Phogat S et al. Conserved structures exposed in HIV-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and potential immunogens. Biochemistry 2002 41 : 7176 82.
61. Srivastava IK, VanDorsten K, Vojtech L, Barnett SW, Stamatatos L. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J Virol 2003 77 : 2310 20.
62. Chakrabarti BK, Kong WP, Wu BY et al. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol 2002 76 : 5357 68.
63. Grundner C, Mirzabekov T, Sodroski J, Wyatt R. Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins. J Virol 2002 76 : 3511 21.
64. Doan LX, Li M, Chen C, Yao Q. Virus-like particles as HIV-1 vaccines. Rev Med Virol 2004 15 : 75 88.
65. Fouts T, Godfrey K, Bobb K et al. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc Natl Acad Sci U S A 2002 99 : 11842 7.
66. Pantophlet R, Wilson IA, Burton DR. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J Virol 2003 77 : 5889 901.
67. Pantophlet R, Wilson IA, Burton DR. Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. Protein Eng Des Sel 2004 17 : 749 58.
68. Brunel FM, Zwick MB, Cardoso RM et al. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. J Virol 2006 80 : 1680 7.
69. Zhou T, Xu L, Dey B et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007 445 : 732 37.
70. Li Y, Svehla K, Mathy NL, Voss G, Mascola JR, Wyatt R. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol 2006 80 : 1414 26.
71. Tighe H, Takabayashi K, Schwartz D et al. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol 2000 30 : 1939 47.
72. Wille-Reece U, Flynn BJ, Lore K et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci U S A 2005 102 : 15190 4.
73. Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol 2005 174 : 7676 83.
74. Geijtenbeek TB, Kwon DS, Torensma R et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000 100 : 587 97.
75. Boggiano C, Manel N, Littman DR. Dendritic cell-mediated trans-enhancement of HIV-1 infectivity is independent of DC-SIGN. J Virol 2006 82 : 2519 23.
76. Boyd MR, Gustafson KR, McMahon JB et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother 1997 41 : 1521 30.
77. Esser MT, Mori T, Mondor I et al. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. J Virol 1999 73 : 4360 71.
78. Desrosiers RC, Wyand MS, Kodama T et al. Vaccine protection against simian immunodeficiency virus infection. Proc Natl Acad Sci U S A 1989 86 : 6353 7.
79. Murphey-Corb M, Martin LN, Davison-Fairburn B et al. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 1989 246 : 1293 7.
80. Gomez MB, Hildreth JE. Antibody to adhesion molecule LFA-1 enhances plasma neutralization of human immunodeficiency virus type 1. J Virol 1995 69 : 4628 32.
81. Rizzuto CD, Sodroski JG. Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. J Virol 1997 71 : 4847 51.
82. Landau NR, Warton M, Littman DR. The envelope glycoprotein of the human immunodeficiency virus binds to the immunoglobulin-like domain of CD4. Nature 1988 334 : 159 62.
83. Brighty DW, Rosenberg M, Chen IS, Ivey-Hoyle M. Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor. Proc Natl Acad Sci U S A 1991 88 : 7802 5.
84. Daar ES, Ho DD. Relative resistance of primary HIV-1 isolates to neutralization by soluble CD4. Am J Med 1991 90 : 22S 6.
85. Allaway GP, Davis-Bruno KL, Beaudry GA et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 1995 11 : 533 9.
86. Zhu P, Olson WC, Roux KH. Structural flexibility and functional valence of CD4-IgG2 (PRO 542): potential for cross-linking human immunodeficiency virus type 1 envelope spikes. J Virol 2001 75 : 6682 6.
87. Castagna A, Biswas P, Beretta A, Lazzarin A. The appealing story of HIV entry inhibitors: from discovery of biological mechanisms to drug development. Drugs 2005 65 : 879 904.
88. Gauduin MC, Allaway GP, Olson WC, Weir R, Maddon PJ, Koup RA. CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus type 1 isolates. J Virol 1998 72 : 3475 8.
89. Jacobson JM, Israel RJ, Lowy I et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother 2004 48 : 423 9.
90. Healey D, Dianda L, Moore JP et al. Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding. J Exp Med 1990 172 : 1233 42.
91. Moore JP, Sattentau QJ, Klasse PJ, Burkly LC. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J Virol 1992 66 : 4784 93.
92. Zhou T, Hamer DH, Hendrickson WA, Sattentau QJ, Kwong PD. Interfacial metal and antibody recognition. Proc Natl Acad Sci U S A 2005 102 : 14575 80.
93. Burkly L, Mulrey N, Blumenthal R, Dimitrov DS. Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies. J Virol 1995 69 : 4267 73.
94. Liu R, Paxton WA, Choe S et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996 86 : 367 77.
95. Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB. Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 1997 16 : 100 3.
96. Dean M, Carrington M, Winkler C et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996 273 : 1856 62.
97. Samson M, Libert F, Doranz BJ et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996 382 : 722 5.
98. Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 1996 35 : 3362 7.
99. Samson M, Soularue P, Vassart G, Parmentier M. The genes encoding the human CC-chemokine receptors CC-CKR1 to CC-CKR5 (CMKBR1-CMKBR5) are clustered in the p21.3-p24 region of chromosome 3. Genomics 1996 36 : 522 6.
100. Zhou Y, Kurihara T, Ryseck RP et al. Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J Immunol 1998 160 : 4018 25.
101. Lopalco L, Barassi C, Pastori C et al. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vitro. J Immunol 2000 164 : 3426 33.
102. Lopalco L, Pastori C, Cosma A et al. Anti-cell antibodies in exposed seronegative individuals with HIV type 1-neutralizing activity. AIDS Res Hum Retroviruses 2000 16 : 109 15.
103. Pastori C, Weiser B, Barassi C et al. Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. Blood 2006 107 : 4825 33.
104. Shaheen F, Collman RG. Co-receptor antagonists as HIV-1 entry inhibitors. Curr Opin Infect Dis 2004 17 : 7 16.
105. Dragic T, Trkola A, Thompson DA et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci U S A 2000 97 : 5639 44.
106. Baba M, Miyake H, Wang X, Okamoto M, Takashima K. Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Antimicrob Agents Chemother 2007 51 : 707 15.
107. Marozsan AJ, Kuhmann SE, Morgan T et al. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005 338 : 182 99.
108. Trkola A, Kuhmann SE, Strizki JM et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A 2002 99 : 395 400.
109. Kuhmann SE, Platt EJ, Kozak SL, Kabat D. Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J Virol 2000 74 : 7005 15.
110. Lee B, Sharron M, Blanpain C et al. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem 1999 274 : 9617 26.
111. Wu L, Gerard NP, Wyatt R et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996 384 : 179 83.
112. McKnight A, Wilkinson D, Simmons G et al. Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent. J Virol 1997 71 : 1692 6.
113. Strizki JM, Turner JD, Collman RG, Hoxie J, Gonzalez-Scarano F. A monoclonal antibody (12G5) directed against CXCR-4 inhibits infection with the dual-tropic human immunodeficiency virus type 1 isolate HIV-1(89.6) but not the T-tropic isolate HIV-1(HxB). J Virol 1997 71 : 5678 83.
114. Leyland-Jones B. Trastuzumab: hopes and realities. Lancet Oncol 2002 3 : 137 44.
115. Zuber B, Hinkula J, Levi M, Lundholm P, Nilsson C, Wahren B. Induction of immune responses and break of tolerance by DNA against the HIV-1 co-receptor CCR5 but no protections from SIV SM challenge. Virology 2000 633 : 1 10.
116. Chackerian B, Briglio L, Albert PS, Lowy DR, Schiller JT. Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus. J Virol 2004 78 : 4037 47.
117. Khurana S, Kennedy M, King LR, Golding H. Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity. J Virol 2005 79 : 6791 800.
118. Mirzabekov T, Kontos H, Farzan M, Marasco W, Sodroski J. Paramagnetic proteoliposomes containing a pure, native, and oriented seven-transmembrane segment protein, CCR5. Nat Biotechnol 2000 18 : 649 54.
119. Navratilova I, Pancera M, Wyatt RT, Myszka DG. A biosensor-based approach toward purification and crystallization of G protein-coupled receptors. Anal Biochem 2006 353 : 278 83.
120. Navratilova I, Sodroski J, Myszka DG. Solubilization, stabilization, and purification of chemokine receptors using biosensor technology. Anal Biochem 2005 339 : 271 81.
121. Ji C, Brandt M, Dioszegi M et al. Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities. Antiviral Res 2006 74 : 125 37.
122. Steinberger P, Sutton JK, Rader C, Elia M, Barbas CF III. Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization. J Biol Chem 2000 275 : 36073 8.
123. Zhang Y, Pool C, Sadler K et al. Selection of active ScFv to G-protein-coupled receptor CCR5 using surface antigen-mimicking peptides. Biochemistry 2004 43 : 12575 84.
124. Dalum I, Jensen MR, Hindersson P, Elsner HI, Mouritsen S. Breaking of B cell tolerance toward a highly conserved self protein. J Immunol 1996 157 : 4796 804.
125. Tremblay MJ, Fortin JF, Cantin R. The acquisition of host-encoded proteins by nascent HIV-1. Immunol Today 1998 19 : 346 51.
126. Lederman MM, Veazey RS, Offord R et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004 306 : 485 7.
127. Veazey RS, Klasse PJ, Schader SM et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005 438 : 99 102.
128. Hoxie JA, Fitzharris TP, Youngbar PR, Matthews DM, Rackowski JL, Radka SF. Nonrandom association of cellular antigens with HTLV-III virions. Hum Immunol 1987 18 : 39 52.
129. Lando Z, Sarin P, Megson M et al. Association of human T-cell leukaemia/lymphoma virus with the Tac antigen marker for the human T-cell growth factor receptor. Nature 1983 305 : 733 6.
130. Young JA, Bates P, Willert K, Varmus HE. Efficient incorporation of human CD4 protein into avian leukosis virus particles. Science 1990 250 : 1421 3.
131. Stott EJ, Chan WL, Mills KH et al. Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine. Lancet 1990 336 : 1538 41.
132. Stott EJ. Anti-cell antibody in macaques. Nature 1991 353 : 393.
133. Arthur LO, Bess JW Jr., Sowder RC II. et al. Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 1992 258 : 1935 8.
134. Esser MT, Graham DR, Coren LV et al. Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: implications for viral pathogenesis and immune regulation. J Virol 2001 75 : 6173 82.
135. Frank I, Stoiber H, Godar S et al. Acquisition of host cell-surface-derived molecules by HIV-1. AIDS 1996 10 : 1611 20.
136. Orentas RJ, Hildreth JE. Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV. AIDS Res Hum Retroviruses 1993 9 : 1157 65.
137. Chan WL, Rodgers A, Hancock RD et al. Protection in simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response. J Exp Med 1992 176 : 1203 7.
138. Arthur LO, Bess JW Jr., Urban RG et al. Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J Virol 1995 69 : 3117 24.
139. Stott JAN, Kent K, Kitchin P et al. Viral and Cellular Antigens induce Protection Against Simian Immunodeficiency Virus Infection of Macaques. Biotechnology and AIDS. Rome : Instituto Polignafico, 1995 151 9.
140. Page M, Ojugo A, Imami N, Hardy G, Gotch F, Almond N. Specificity of anti-human leukocyte antigen antibody responses after immunization with Remune, an inactivated HIV-1 vaccine. AIDS 2007 21 : 375 7.
141. Bergmeier LA, Lehner T Innate and adaptive mucosal immunity in protection against HIV infection. Adv Dent Res 2006 19 : 21 8.
142. MacDonald KS, Embree J, Njenga S et al. Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 1998 177 : 551 6.
143. Coombs RW, Reichelderfer PS, Landay AL. Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS 2003 17 : 455 80.
144. Dela Cruz CS, MacDonald KS, Barber BH. Anti-major histocompatibility complex antibody responses in macaques via intradermal DNA immunizations. Vaccine 2000 18 : 3152 65.
145. Lifson JD, Piatak M Jr., Rossio JL et al. Whole inactivated SIV virion vaccines with functional envelope glycoproteins: safety, immunogenicity, and activity against intrarectal challenge. J Med Primatol 2002 31 : 205 16.
146. Altman JD, Moss PA, Goulder PJ et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996 274 : 94 6.
147. Kern F, LiPira G, Gratama JW, Manca F, Roederer M. Measuring Ag-specific immune responses: understanding immunopathogenesis and improving diagnostics in infectious disease, autoimmunity and cancer. Trends Immunol 2005 26 : 477 84.
148. Eisenbarth GS, Nepom GT. Class II peptide multimers: promise for type 1A diabetes Nat Immunol 2002 3 : 344 5.
149. McMichael AJ, Kelleher A. The arrival of HLA class II tetramers. J Clin Invest 1999 104 : 1669 70.
150. Moro M, Cecconi V, Martinoli C et al. Generation of functional HLA-DR*1101 tetramers receptive for loading with pathogen- or tumour-derived synthetic peptides. BMC Immunol 2005 6 : 24.
151. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995 373 : 123 6.
152. Wei X, Ghosh SK, Taylor ME et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995 373 : 117 22.
153. Bounou S, Leclerc JE, Tremblay MJ. Presence of host ICAM-1 in laboratory and clinical strains of human immunodeficiency virus type 1 increases virus infectivity and CD4(+)-T-cell depletion in human lymphoid tissue, a major site of replication in vivo. J Virol 2002 76 : 1004 14.
154. Fortin JF, Cantin R, Lamontagne G, Tremblay M. Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J Virol 1997 71 : 3588 96.